7,701 Shares in Natera, Inc. $NTRA Bought by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,701 shares of the medical research company’s stock, valued at approximately $2,090,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NTRA. UBS Group AG grew its position in shares of Natera by 19.4% in the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after buying an additional 71,355 shares during the last quarter. Fifth Third Bancorp lifted its position in Natera by 3,373.1% during the first quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock valued at $2,251,000 after acquiring an additional 10,929 shares during the last quarter. ABN Amro Investment Solutions lifted its position in Natera by 44.6% during the first quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock valued at $1,869,000 after acquiring an additional 2,883 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Natera by 286.8% in the fourth quarter. Teacher Retirement System of Texas now owns 65,717 shares of the medical research company’s stock valued at $15,055,000 after acquiring an additional 48,728 shares in the last quarter. Finally, SBI Okasan Asset Management Co.Ltd. acquired a new stake in Natera in the fourth quarter valued at approximately $1,897,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 3,076 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer directly owned 99,897 shares of the company’s stock, valued at $26,611,561.83. This represents a 2.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the transaction, the chief financial officer owned 51,637 shares of the company’s stock, valued at $14,159,898.14. This trade represents a 0.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 181,045 shares of company stock valued at $41,330,968 over the last three months. 5.05% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Piper Sandler upped their price target on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research report on Wednesday. Wolfe Research initiated coverage on Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective for the company. Canaccord Genuity Group set a $375.00 target price on Natera in a research note on Friday, August 7th. Royal Bank Of Canada boosted their target price on Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. Finally, Barclays reaffirmed an “overweight” rating and set a $340.00 target price on shares of Natera in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $319.38.

Natera Trading Down 0.3%

NASDAQ:NTRA opened at $309.93 on Friday. Natera, Inc. has a twelve month low of $156.71 and a twelve month high of $326.03. The company has a market cap of $44.67 billion, a PE ratio of -227.89 and a beta of 1.51. The company’s 50 day moving average is $263.76 and its two-hundred day moving average is $226.40.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.74) earnings per share. As a group, analysts expect that Natera, Inc. will post -1.11 EPS for the current fiscal year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.